MIA shines in poster session

22 November 2019
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
PhD student Grace Attrill presented her work on possible biomarkers of response in Stage III melanoma patients treated with anti-PD-1 immunotherapy. She has found that a specific population of immune cell appears in higher numbers in patients who were treated with anti-PD-1 and did not recur. Her research also found that another subpopulation of immune cells may be associated with increased risk of melanoma recurrence. Grace’s poster notes that these immune cells could be a possible biomarker that may indicate which patients will respond well to immunotherapy.
Recent PhD graduate Dr Tuba Nur Gide, also presented a poster on immune cells in melanoma patients treated with immunotherapy. Dr Gide looked at the distribution of specific immune cells in relation to patient response. She found a significant association between response to immunotherapy and a very short distance between immune cells and melanoma cells. A higher amount of these immune cells that were close to patient melanoma cells also related to better progression-free survival for patients on immunotherapy. These findings could also be used to create better biomarkers of patient response.
Another PhD student, Jarem Edwards, presented his research on tumour mutation burden as a possible factor in patient survival. He found that the number of mutations in a patient’s melanoma was not predictive of the amount of immune cells, nor did they predict response or survival in melanoma patients.
Finally, medical oncology fellow, Dr Lalit Pallan, presented his poster on clinical predictors of outcome in melanoma patients with brain metastases treated with combination immunotherapy. Clinicopathological characteristics of patients are those that can be observed by clinicians through minimally invasive techniques such as scans and blood tests. Dr Pallan found that levels of LDH (an enzyme regularly tested for in the blood of melanoma patients), the number of brain metastases, and prior treatments may be factors that could help clinicians determine the likely outcome of treatment. Notably, patients with a lower burden of brain metastases that are asymptomatic and are treated for the first time with combination immunotherapy are more likely to respond to their treatment and have longer progression-free and overall survival.

A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Professor Georgina Long hands on baton of SMR Presidency
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.

City2Surf 2020
Join in the fun of the virtual event, and together we can run over melanoma!

Top melanoma experts at MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Top melanoma experts from MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Melanoma Supportive Care Needs research study.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Research reveals long-term benefit of adjuvant therapy for Stage III melanoma

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

New online melanoma risk calculators critical to saving lives
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Professor Richard Scolyer receives University of Sydney Alumni Award.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Uniting together despite the distance
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Important Update: Masks required at Poche Centre
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.